COVID-19 Funding Opportunities

The MSI STEM Research & Development Consortium (MSRDC) - Additional funding for COVID-19-related research

The MSI STEM Research & Development Consortium (MSRDC)

The Icahn School of Medicine at Mount Sinai has become a partner institution of the MSI STEM Research & Development Consortium (MSRDC). This partnership offers significant advantages to Mount Sinai researchers and the consortium members through collaborative work. It also offers funding opportunities that would otherwise be unavailable to Mount Sinai researchers.  MSRDC awards are “other transactions” rather than traditional grants or contracts. These non-competed awards bypass solicitation, allowing for a direct connection between collaborative partners and government program managers. This unusual funding mechanism connect collaborative partners with Minority-Serving Institutions (MSI), such as Historically Black Colleges and Universities (HBCUs), to work on government projects.

Some Advantages – Skip The Line:

  • Access a community of researchers and partners
  • Leverage unique funding vehicles to secure direct, non-competed awards
  • Work together to produce a Scope of Work (SOW) and a Request for Proposal (RFP)
  • Move your idea from concept to award in as few as 90 days, (or fewer)

Some of the federal agencies involved include:

  • Centers for Disease Control and Prevention (CDC)
  • National Institutes of Health (NIH)
  • Food and Drug Administration (FDA)
  • Department of State (DOS)
  • Department of Defense (DoD)
  • Department of Education (DoE)
  • Homeland Security
  • Communications-Electronics Research Development Center (CERDEC)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Army Material Systems Analysts Activity (AMSAA)
  • Department of Transportation

MSRDC Innovation Prospectus
MSRDC  Presentation

Submit your capabilities to get started.  For additional information or assistance, email Anthony Smalls.

Anthony Smalls, MBA
Program Manager
Research Operations & Infrastructure
Icahn School of Medicine at Mount Sinai
New York, NY 10029
Phone:  (212) 241- 0640

If you have any questions for MSRDC, please contact them below:
info@msrdconsortium.org (All other inquiries)
busdev@msrdconsortium.org (For questions about working with our partners and member institutions)
awards@msrdconsortium.org (For those who already have an active research award)

Hours:   Monday to Friday, 9:00 am to 5:00 pm EST
Phone: (202) 684-7953

 

MSHS Guideline for Deans Funding for COVID-19 Research

Send one page proposals, biosketch, and budget—as one PDF—to covidpilotgrants@mssm.edu.

General Notices

NOT-AI-20-066 - Notice of Early Expiration of NOT-AI-20-051 Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

10/30/2020 - NOT-MH-20-073 - Request for Information (RFI): Fostering Innovative Research to Improve Mental Health Outcomes Among Minority and Health Disparities Populations

The National Institute of Mental Health seeks time-sensitive input from all interested parties on the most innovative research and research priorities to improve mental health outcomes among racial/ethnic minority and health disparities populations.

Response Date: October 30, 2020

More Information

NOT-HD-20-017 - Notice of NICHD Participation in NOT-EB-20-012 "Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)"

Notice Number: NOT-HD-20-017

The purpose of this Notice is to inform potential applicants that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is participating in NOT-EB-20-012 “Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)”.

More Information

NOT-MH-20-061 - Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-MH-20-061

The purpose of this Notice is to extend the data-harmonization effort at the National Institute of Mental Health (NIMH) announced in NOT-MH-15-009 to research protocols pertaining to the public health emergency caused by Coronavirus Disease 2019 (COVID-19), the disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

NIMH has already made a significant investment in a data repository to hold human subjects data related to mental illness and related fields. This repository allows data from multiple sources to be aggregated and easily accessed by the research community. However, the data repository is most useful when research laboratories collect data using the same set of data elements. With this Notice, NIMH offers guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes that were previously discussed in NOT-MH-15-009and a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2 virus (the virus that causes COVID-19). The goal of this Notice is to reduce proliferation of one-off survey items and to facilitate data integration, collaboration, and comparisons across data sets.

More Information

Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis

Notice Number: NOT-CA-20-054

The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

More Information

Notice of Participation of National Institute of Nursing Research (NINR) in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional")

Notice Number: NOT-NR-20-005

The purpose of this Notice is to inform applicants that the National Institute of Nursing Research (NINR) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

  • NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
  • NSF encourages the research community to respond to this challenge through existing funding opportunities.
  • In addition, NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov.
  • Complete guidance on submitting a RAPID proposal may be found in Chapter II.E.1 of the NSF Proposal and Award Policies and Procedures Guide.

More Information

NIH Administrative Supplements

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC’s web site to ensure they meet the IC’s requirements.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.

Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.

More Information

Notice of Changes to Funding Opportunities

NOT-HL-20-806 - NHLBI confirms participation in NOT-OD-20-119, NOT-OD-20-120, and NOT-OD-20-121 (Research on COVID-19 Testing among Underserved and/or Vulnerable Populations)

Notice Number: NOT-HL-20-806

More Information

NOT-OD-20-157 - Notice to Clarify and Correct Eligibility in Notices of Special Interest under the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) Program

Notice Number: NOT-OD-20-157

This notice makes corrections to clarify eligibility information in NOT-OD-20-119 “Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations” and NOT-OD-20-120 “Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations” and a deletion to correct responsiveness information for NOT-OD-20-119.

In both NOT-OD-20-119 and NOT-OD-20-120 where it

Currently states:

Eligibility

Eligible existing grants that can be revised in response to this NOSI are limited to eligible non-fellowship active research and resource grants and cooperative agreements. Currently funded grantees may apply for work that is related to their funded project, whether within the scope or outside of the scope of the current project, regardless of the time remaining on the current project. Grants currently in a no-cost extension are eligible to apply

is Updated to read:

Eligibility

Active research and resource grants, cooperative agreements, and small business grants (SBIR and STTRs) are eligible to apply. NRSA training and fellowship grants, and career development awards are not eligible to apply for funding. Currently funded recipients may apply regardless of the time remaining on the current project.Grants currently in a no-cost extension are eligible to apply.

For NOT-OD-20-119, an error is corrected by removal of a bulleted item, related to “Applications nonresponsive to this NOSI…”.

Where it is indicated:

Applications nonresponsive to terms of this NOSI will not be considered.The following types of projects would generally not be appropriate and may be deemed non-responsive:

Remove the bulleted line:

  • Projects that have limited testing capacity, that do not include FDA-authorized testing strategies or present a plan to incorporate approved testing strategies

More Information

NOT-OD-20-156 - Notice of Change to Funding Announcement (NOT-OD-20-048) by the Office of Research on Women's Health (ORWH), " Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)"

Notice Number: NOT-OD-20-156

The purpose of this notice is to inform potential applicants that the Office of Research on Women’s Health (ORWH) has made some changes, effective immediately, in NOT-OD-20-048, “Notice of Special Interest: Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)”.

The following text has been added to reflect changes in the NOSI (NOT-OD-20-048).

The Office of Research on Women’s Health (ORWH) announces the availability of administrative supplements to support research highlighting health disparities among women in the US who are underrepresented, understudied, and underreported (U3) in biomedical research. The proposed research must address at least one objective from the strategic goals 1, 2, or 3 of the 2019-2023 Trans-NIH Strategic Plan for Women’s Health Research “Advancing Science for the Health of Women.”

ORWH is encouraging application submissions and is seeking to support studies on the SARS-CoV-2 virus or COVID-19 disease in alignment with efforts across NIH to develop and implement effective therapeutics and vaccines and to accelerate research on technologies to validate and improve programs that will overcome barriers and increase uptake of effective therapeutics and vaccines at the point of care. Within the focus of this funding opportunity announcement, research topics of interest could include investigating the risk factors associated with COVID-19 disease prevalence among NIH-designated health disparity populations, women living in underserved rural or urban settings, pregnant and lactating women, women frontline healthcare workers, women with low socioeconomic status, and women experiencing homelessness or having justice system involvement.

Topics addressing intersectional and community-based research for older underserved women, residents of skilled nursing or long-term care facilities, and women providing care in the home to aging, disabled populations, or children (i.e., maternal caregiving) are areas of interest.

Research involving qualitative and quantitative techniques to assess social and behavioral processes that affect SARS-CoV-2 infection vulnerability and disease severity in underrepresented, understudied, and underreported (U3) populations are also areas of interest.

Proposals are encouraged to incorporate a variety of media, such as graphic medicine or other arts-based approaches to engage with underrepresented, understudied, and underreported (U3) populations to achieve the goals of the applications.

More Information

NOT-OD-20-149 - Notice of Correction to RFA-OD-20-013 "Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)" for Award Information about Clinical Trials

Notice Number: NOT-OD-20-149

This notice corrects RFA-OD-20-013 “Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)” in Section II. to indicate that this funding opportunity accepts applications that either propose or do not propose clinical trial(s).

This funding opportunity announcement is corrected for Section II. Award Information – Clinical Trial?, as follows:

Currently reads:

Not Allowed: Only accepting applications that do not propose clinical trial

Is modified to read:

Optional: Accepting applications that either propose or do not propose clinical trial(s)

More Information

NOT-HL-20-801- National Heart, Lung, and Blood Institute -Notice of NHLBI Participation in NOT-OD-20-097 "NOSI regarding Availability of Admin Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

Notice Number: NOT-HL-20-801

The purpose of this Notice is to inform potential applicants that NHLBI’s participation in NOT-MH-20-053 “Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19” will cease on July 31, 2020. An application submitted in response to NOT-MH-20-053 that is intended for NHLBI and received on August 01, 2020 or later will be withdrawn.

More Information

NOT-HL-20-799 - National Heart, Lung, and Blood Institute- Notice of NHLBI Participation in NOT-OD-20-097 "Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences"

Notice Number: NOT-HL-20-799

The purpose of this Notice is to inform potential applicants that NHLBI’s participation in NOT-OD-20-097 “Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences” will cease on July 31, 2020. An application submitted in response to NOT-OD-20-097 that is intended for NHLBI and received on August 01, 2020 or later will be withdrawn.

More Information

NOT-AG-20-036 - Notice of NIA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-AG-20-036

This Notice informs potential applicants that the National Institute on Aging (NIA) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional).”

More Information

NOT-DA-20-061 - Notice of NIDA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-DA-20-061

The purpose of this Notice is to inform potential applicants that the National institute of Drug Abuse (NIDA) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-DC-20-010 - Notice of NIDCD's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-DC-20-010

The purpose of this Notice to inform potential applicants that the National Institute on Deafness and Other Communication Disorders (NIDCD) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional).”

More Information

NOT-OD-20-111 - Notice of ORWH Participation in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”

Notice Number: NOT-OD-20-111

The purpose of this Notice is to inform potential applicants that the Office of Research on Women’s Health (ORWH) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-MH-20-064 - Notice of NIMH Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-MH-20-064

The purpose of this Notice is to inform potential applicants that the National Institute of Mental Health (NIMH) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-DK-20-026 - Notice of Additional Activity Code Accepted for "NOT-DK-20-018, Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK"

Notice Number: NOT-DK-20-026

The purpose of this Notice is to add the U24 activity code to the activity codes eligible for submissions and adjust the language for parent awards to be eligible under NOT-DK-20-018: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK.

More Information

NOT-AA-20-007 - Notice of Participation of NIAAA in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional"

Notice Number: NOT-AA-20-007

The purpose of this Notice is to inform applicants that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-CA-20-048 - Notice of National Cancer Institute (NCI) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Notice Number: NOT-CA-20-048

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in PA-18-935, “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).”

More Information

NOT-DC-20-003 - Notice of NIDCD's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-DC-20-003

The purpose of this Notice is to inform applicants that the National Institute on Deafness and Other Communication Disorders (NIDCD) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”. The following changes and updates are made to PA-18-935 (shown in italics) to reflect NIDCD’s participation in this funding opportunity announcement (FOA).

More Information

NOT-HG-20-034 - Notice of NHGRIs Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-HG-20-034

The purpose of this Notice is to inform applicants that the National Human Genome Research Institute (NHGRI) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

NOT-MD-20-018 - Notice of Participation of the National Institute on Minority Health and Health Disparities (NIMHD) in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Notice Number: NOT-MD-20-018

The purpose of this Notice to inform potential applicants that the National Institute on Minority Health and Health Disparities (NIMHD) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).”

More Information

NOT-TR-20-015 - Notice of NCATS' Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-TR-20-015

The purpose of this Notice is to inform applicants that the National Center for Advancing Translational Sciences (NCATS) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

Request for Proposal

NOT-CA-20-077 - Request for Proposals (RFP) Solicitation S20-119: Serological Sciences Network Capacity Building Centers

Notice Number: NOT-CA-20-077

Leidos Biomedical Research, Inc. (Leidos Biomed) has issued an RFP for Capacity Building Centers to support the Serological Sciences Network (SeroNet), developed to mobilize collaborative efforts to develop serological assays of high specificity and high sensitivity for deployment to test for SARS-CoV-2 induced immune responses and to rapidly expand national serological testing capacity.

More Information

NIH NOSI (Notice of Special Interest)

NOT-AT-20-011 - Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AT-20-011

NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

NOT-EB-20-003 - Notice of NIBIB's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-EB-20-003

The purpose of this Notice is to inform applicants that the National Institute of Biomedical Imaging and Bioengineering (NIBIB) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

10/05/2020 to 06/16/2023 - NOT-HD-20-021 - National Institute of Child Health and Human Development/NIH/DHHS - Notice of Special Interest (NOSI): Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract

Notice Number: NOT-HD-20-021

Submission Dates: 05-Oct-2020 , 16-Oct-2020 , 05-Feb-2021 , 16-Feb-2021 , 05-Jun-2021 , 16-Jun-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Feb-2022 , 16-Feb-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Feb-2023 , 16-Feb-2023 , 05-Jun-2023 , 16-Jun-2023

The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.

More Information

10/05/2020 to 05/07/2021- NOT-MD-20-026 - National Institute on Minority Health and Health Disparities/NIH/DHHS - Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations

Notice Number: NOT-HL-20-757

05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021

The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.

The NOSI is not a funding opportunity in itself. You must apply to the appropriate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

10/06/2020 - NOT-HL-20-757: Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-HL-20-757

NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

First Available Due Date: March 17, 2020
Expiration Date: October 06, 2020

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

10/17/2020 - NOT-TR-20-012: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Notice Number: NOT-TR-20-012

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

First Available Due Date: June 05, 2020
Expiration Date: October 17, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

11/10/2020 - NOT-EB-20-008 - Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-EB-20-008

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years.

Expiration Date: November 11, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

12/30/2020 - NOT-MD-20-022 - Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations

Notice Number: NOT-MD-20-022

NIH-designated U.S. health disparity populations: Racial and ethnic minorities, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities (see https://www.nimhd.nih.gov/about/overview/).

COVID-19 vulnerable populations: Residents of chronic care and assisted living facilities; community-dwelling older adults; individuals with cognitive impairment or dementia; homeless populations; incarcerated populations and those involved with the criminal justice system (e.g., participants of re-entry programs); adults with medical comorbidities; pregnant women; children and adolescents; individuals with substance use disorders or severe mental illness, those living in congregate housing (e.g., shelters, residential treatment or assisted living); persons who are deaf or with disabilities including visual, hearing, communication, or mobility impairment; detainees in immigration centers; migrant communities; individuals living on tribal lands or reservations; and communities that are exposed to high rates of air pollution or other toxic exposures. Vulnerable groups also include those on the frontlines of healthcare during the COVID-19 pandemic, and those working in essential business operations (e.g., grocery and pharmacy workers, transportation, hospital and community janitorial/sanitation workers, waste collectors, postal and other delivery services, warehouse personnel, etc.).

Multilevel Intervention: An intervention at two or more levels of influence, including policy (governing bodies or others who establish policies, rules, or guidelines), community (a group of people living in a defined geographic area or having particular characteristics in common, structural, and/or environmental determinants of health), organizational (large healthcare systems, community health clinics, public health organizations, community-based organizations, social services, schools, workplaces, other service providers, etc.), interpersonal (e.g., communication, social supports, relationships with others), and individual (e.g., community residents, employees, caregivers, family members, providers;). See the NIMHD Research Framework, https://www.nimhd.nih.gov/about/overview/research-framework.html, for examples of health determinants at different levels of influence).

Expiration Date: Dec 30, 2020

More Information

12/30/2020 - NOT-MH-20-053 - Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

Notice Number: NOT-MH-20-053

This Notice of Special Interest (NOSI) highlights interest in research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. While the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact.

Expiration Date: Dec 30, 2020

More Information

2021 NIH NOSI (Notice of Special Interest)

02/06/2021 - NOT-GM-20-025: Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Notice Number: NOT-GM-20-025

NIGMS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19

First Available Due Date: March 25, 2020
Expiration Date: February 06, 2021

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

03/21/2021 - NOT-DA-20-047: Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

Notice Number: NOT-DA-20-047

NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

First Available Due Date: March 19, 2020
Expiration Date: March 31, 2021

More Information

03/25/2021 - NOT-AI-20-034: Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AI-20-034

NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

First Available Due Date: March 25, 2020
Expiration Date: March 25, 2021

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

NOT-AI-20-058 - Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)”

Notice Number: NOT-AI-20-058

The purpose of this Notice is to inform the extramural community that NOT-AI-20-034, “Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)” is rescinded effective immediately. NOT-AI-20-034 is replaced by NOT-AI-20-059 which highlights very specific needs for competitive revision applications to NIAID grants to facilitate the Federal SARS-CoV-2/COVID-19 research response.

Release Date: July 6, 2020

More Information

03/31/2021 - NOT-EB-20-006 - Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-EB-20-006

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years.

Expiration Date: March 31, 2021

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

03/31/2021 - NOT-EB-20-007 - Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-EB-20-007

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years.

Expiration Date: March 31, 2021

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

04/01/2021 - NOT-OD-20-097- Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

Notice Number: NOT-OD-20-097

This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.

Release Date: April 13, 2020
First Available Due Date: April 13, 2020
Expiration Date: April 01, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

April 15, 2021 - NOT-NS-20-051 - Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Notice Number: NOT-NS-20-051

NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Release Date: April 30, 2020
First Available Due Date: May 01, 2020
Expiration Date: April 15, 2021

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

04/16/2021 - NOT-MH-20-047 -Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus

Notice Number: NOT-MH-20-047

NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

Expiration Date: April 16, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

04/16/2021 - NOT-AA-20-011 - Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA

Notice Number: NOT-AA-20-011

The impact of the COVID-19 pandemic on the nation is vast, especially on health and well-being. Research suggests that alcohol consumption tends to increase during times of duress and uncertainty such as disasters and other traumatic events, and as such alcohol is often misused to cope with stress, anxiety, and other uncomfortable emotions. In addition, the misuse of alcohol to cope with the stress as a result of physical distancing and other policy measures, and a lack of access to supportive social networks and treatment for people with pre-existing alcohol use disorder (AUD) are significant concerns during the pandemic. These outcomes are particularly challenging with respect to COVID-19 because alcohol misuse can interfere with normal immune system function and elevate susceptibility to viral infections of the respiratory system. Alcohol-associated damage to the liver, heart, and other organs may also complicate health outcomes in individuals with COVID-19. These myriad physical and behavioral health outcomes related to alcohol and COVID-19 present a range of urgent research needs and opportunities.

Release Date: April 16, 2020
First Available Due Date: May 15, 2020
Expiration Date: April 16, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

05/01/2021 - NOT-AG-20-022 - Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AG-20-022

NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

05/01/2021 - NOT-MD-20-019 - Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities

Notice Number: NOT-MD-20-019

The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

Expiration Date: May 01, 2021

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

05/04/2021 - NOT-ES-20-015 - NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-ES-20-015

NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

Expiration Date: May 04, 2021

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

07/02/2021 - NOT-AI-20-059 - National Institute of Allergy and Infectious Diseases/NIH/DHHS - Notice of Special Interest (NOSI): Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces NOT-AI-20-034 which was rescinded with this issuance of this Notice.

Expiration Deadline: July 2, 2021

More Information

07/10/2021 - NOT-TR-20-011: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Notice Number: NOT-TR-20-011

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

First Available Due Date: May 04, 2020
Expiration Date: July 10, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

07/13/2021 - NOT-OD-20-129 - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project

Notice Number: NOT-OD-20-129

NIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. Because many people with Down syndrome are at increased risk of having co-occurring medical conditions, such as pulmonary disease, cardiac problems, obesity, diabetes, sleep apnea, and altered immune function that may predispose them to more severe infection with SARS-CoV-2, they may be particularly vulnerable to COVID-19 complications. Combined with shared living situations, and reduced access to testing and treatment services due to disparities in provision of resources, the impact of COVID-19 infection in people with Down syndrome is likely to be elevated. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.

More Information

2022 NIH NOSI (Notice of Special Interest)

01/26/2022 - NOT-TR-20-016 - Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

Notice Number: NOT-TR-20-016

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Expiration Date: January 26, 2022

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

01/26/2022 - NOT-TR-20-017 - Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus

Notice Number: NOT-TR-20-017

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Expiration Date: January 26, 2022

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

09/08/2022 - NOT-DC-20-008 - Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

Notice Number: NOT-DC-20-008

Coronavirus Disease 2019 (COVID-19) is a recently emerged human disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

Expiration Date: Sept 8, 2022

More Information

2023 NIH NOSI (Notice of Special Interest)

04/02/2023 - NOT-MH-20-040 - NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training (Admin Supp Clinical Trial Optional)

Notice Number: NOT-MH-20-040

The purpose of the NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training is to support advanced research opportunities for exceptional individuals holding the MD/PhD degree who are early in their research careers and thereby help these individuals transition efficiently and effectively from the period of clinical training to the next stage of their research careers. This administrative supplement program will provide focused, protected research time for eligible individuals during residency and/or clinical fellowship. The proposed research experience must have the potential to contribute significantly to the candidate’s research career.

Release Date: April 14, 2020
First Available Due Date: April 01, 2021
Expiration Date: April 02, 2023

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

2024 NIH NOSI (Notice of Special Interest)

01/28/2024 - NOT-DA-20-058 - Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders

Notice Number: NOT-DA-20-058

There is an urgent need for remotely delivered Substance Use Disorder (SUD) treatments to reduce patient burden and for methods to conduct clinical trials remotely. The purpose of this NOSI is to stimulate research to evaluate the safety and efficacy of telemedicine or remotely provided treatments for SUD, and to develop tools for remote collection of data in clinical trials of treatments for SUD.

Release Date: June 29, 2020
First Available Due Date: October 05, 2020
Expiration Date: January 08, 2024

More Information

Continuous Submission

AIDS United - Relief, Recovery and Resilience Fund

AIDS United is making funds available, through this request for applications, to assist in meeting the needs of organizations serving people living with and at risk for HIV and AIDS, and that are experiencing challenges meeting their community’s needs because of the COVID-19 pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Adira Foundation - Fast-Track Grant Response: COVID-19

As people all over the world are joining together to slow the spread of the coronavirus and its impact on daily life—an effort that changes daily and differs city to city and state to state—Adira Foundation is redirecting some funding to meet immediate and pressing need in our community.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

American College of Chest Physicians - CHEST Foundation COVID-19 Community-based Grant

As the charitable foundation for the American College of Chest Physicians, the CHEST Foundation has a mission of championing lung health by supporting clinical research, patient education, and community service. During this time of need, the CHEST Foundation is focusing efforts on assisting those making a difference in their communities during the COVID-19 pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Biogen - COVID-19 Response Program

The Biogen Foundation has committed $10M to aid in COVID-19 relief efforts around the world. At this time, the Biogen Foundation’s COVID-19 relief efforts are focused on the following categories: expanding and ensuring access to testing; easing the burden on healthcare systems and healthcare workers; and providing food and necessities for our most vulnerable populations.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Bloomberg Philanthropies - Coronavirus Local Response Initiative

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Brookhaven National Laboratory - COVID-19 Research Support

The Center for Biomolecular Structure team is supporting remote macromolecular crystallography experiments at Beamlines 17-ID-1 (AMX) and 17-ID-2 (FMX) for research projects related to COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Brooklyn Community Foundation - Brooklyn COVID-19 Response Fund

Funding Amount: $10,000

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Call for Expert Collaborators: COVID-19 Response

Crowdhelix is seeking researchers & innovators worldwide with a strong track record of excellence in fields relevant to the global effort to tackle the novel coronavirus (COVID-19) pandemic. The sponsor is offering free access to Crowdhelix, their online Open Innovation platform, to experts seeking to collaborate across continents and disciplines in developing R&D funding proposals to help tackle COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Early Treatment Fund (CETF) - Grants Program

CETF will be funding initiatives that focus on treating outpatients with COVID-19 to prevent hospitalization. Grant recipients are required to share what they learn with others.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Fast Track Access

To facilitate research on COVID-19, CERIC has set up a dedicated Fast Track Access to a selected number of instruments including 600 and 800 MHz NMR, SAXS light scattering laboratory, Cryo EM, synchotron beamlines for Small Angle X-ray scattering and X-ray diffraction, and Synchroton Infrared Source for Spectroscopy and Imagine. Due to the travel restrictions in place for several countries, remote access will be preferred.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 HPC Consortium

The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. XSEDE hopes to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections. Consortium members manage a range of computing capabilities that span from small clusters to some of the very largest supercomputers in the world.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Relief Fund

Robin Hood anticipates making grants to 501(c)(3) organizations in New York City that are well-positioned to serve low-income communities. The initial grants, expected to last three months in duration, will average $45,000.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Diamond Light Source - Rapid Access Call for Proposals: SARS-CoV-2

As part of Diamond’s effort to combat COVID-19 (as demonstrated by the fragment screening campaign against SAR-CoV-2 Main protease), fragment screening expertise and infrastructure are offered to users working on Covid-19 related projects.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

European Synchrotron Radiation Facility - Covid-19 Scientific Research

The ESRF is ready to provide access to its facilities for Covid-19 related research projects. This exceptional access will be granted with the aim to contribute to the international scientific effort to overcome the covid-19 pandemic.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Euro-Bioimaging - Fast Track Access to Biological and Biomedical Imaging Technologies for COVID-19 Research Projects

This opportunity offers access to biomedical imaging technologies to to scientists who have COVID-19 related research projects that need imaging resources.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

European Synchrotron Radiation Facility - Mail-in Protein-to-Structure Services to Support Structural Biology Research Related to COVID-19 at the EMBL Grenoble HTX Lab and the Joint ESRF-EMBL MX Beamlines

The ESRF-EMBL Joint Structural Biology Group (JSBG) invite COVID-19 related proposals that can benefit from the seamless integration of the EMBL High throughput Crystallization Facility (HTX Lab) with the highly automated JSBG MX beamlines at the ESRF. The pipeline starts with mail-in samples and integrates crystallization screening, crystal optimization, ligand soaking if required and eventually fragment screening with libraries of up to 1200 fragments. Crystals obtained will be automatically harvested and passed to the ESRF for automated X-ray data collection, with real-time access to experimental results and parameters. This pipeline is uniquely suited to support of structural biology projects in conditions of confinement and restricted access to labs. The HTX lab is already accepting crystallization projects on COVID-19 related research and three ESRF beamlines (MASSIF-1 (ID30A-1), ID30B and ID23-2) will become operational after 11 May 2020.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Fast Grants

Emergent Ventures invites applications from scientists at academic institutions currently working on a COVID-19 related project and in need of funding. Fast Grants are $10,000 to $500,000 and decisions are made in under 48 hours.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Federal Communications Commission - COVID-19 Telehealth Program

The COVID-19 Telehealth Program will provide $200 million in funding, appropriated by Congress as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help health care providers provide connected care services to patients at their homes or mobile locations in response to the novel Coronavirus 2019 disease (COVID-19) pandemic.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Funeral Services Foundation - COVID-19 Crisis Response Fund

This fund is designed to be flexible and will provide grants for immediate needs including funeral service emergency response to significant loss of life, to organizations and resources providing service to families with unresolved and complicated grief due to loss during this crisis, and for other important needs of the funeral service profession and the families served. The Fund will consider proposals from US 501(c)3 nonprofit organizations and Canadian registered charities.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Ginkgo Bioworks - Access to Platform for Partner COVID-19 Projects

Ginkgo Bioworks has committed its platform to supporting research and development efforts for COVID-19, including $25M of free access to its infrastructure.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Global Innovation Fund Grant Program

The Global Innovation Fund was set up to confront global development challenges by funding innovations with the potential to improve the lives of the world’s poorest people. GIF will devote resources to new deals for COVID-19-related grantmaking in 2020.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

ICESCO prize for Fighting against Coronavirus

In response to the World Health Organization’s appeal to the international community to “seize every opportunity to curb, contain, combat, and delay the spread of the virus, and mitigate its impact”, the Islamic World Education, Scientific, and Cultural Organization (ICESCO) announces its Prize for Fighting Novel Coronavirus (COVID-19). The amount of the prize is US$200,000, including an award medal.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Innovations for Poverty Action - Competitive Fund for Peace and Recovery

Submission Deadline Not Posted

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Jacob and Valeria Langeloth Foundation - COVID-19 Rapid Response Fund

The Jacob and Valeria Langeloth Foundation created the COVID-19 Rapid Response Fund (CRRF) to enable Langeloth to address organizations’ urgent and critical needs that have arisen due to the COVID-19 global pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Jameel (Abdul Latif) Poverty Action Lab (J-PAL) - J-PAL North America Short Term Research Management Program (STReaM)

Research projects may need to adapt quickly in the context of COVID-19. The Short Term Research Management program (STReaM) makes experienced research management staff available to help researchers in the North America region navigate these challenges. STReaM will continue to accept requests for support through its regular application process. The team can offer hands-on support to help think through challenging obstacles, such as impacts to timelines, adapting to virtual research methods, and navigating difficult conversations with stakeholders. Researchers conducting projects in the North America region are invited to request this support, regardless of the project phase.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Jameel (Abdul Latif) Poverty Action Lab (J-PAL) - J-PAL North America US Health Care Delivery Initiative (HCDI)

As always, HCDI is open to receiving off-cycle proposals on time-sensitive topics. HCDI welcomes proposals that focus on producing evidence that North America decision-makers can act upon promptly to respond to the current crisis. Please note that the sponsor will not accept human subjects research requiring in-person interactions with subjects.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

National Institute of Allergy and Infectious Diseases/NIH/DHHS - Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)

The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS - Rapid Acceleration of Diagnostics (RADx): Fast-Track Program for COVID-19 Test Development and Distribution

National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)

07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021

National Institute of Biomedical Imaging and Bioengineering (NIBIB) invites applications for exploratory/developmental research programs of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). hese studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Research Project Grant (R01 Clinical Trial Required)

07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021

NIH invites applications for discrete, specified, circumscribed projects in areas representing the specific interests and competencies of the investigator(s). This NIBIB Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of the NIBIB. For this Funding Opportunity Announcement, NIBIB will only support R01 applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development. NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials or trials in which the primary outcome is efficacy, effectiveness or a post-market concern. This FOA will use the NIH Research Project (R01) award mechanism.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022, 16-Feb-2022, 07-May-2022, 16-Jun-2022, 07-Sep-2022, 16-Oct-2022, 07-Jan-2023
This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data.

A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal.All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

Application Deadlines: 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Application Deadlines: 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.   This Funding Opportunity Announcement does not accept applications proposing clinical trial(s

Application Deadlines: 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 05-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH/DHHS - RFA-TR-20-003 -- Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)

The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

National Science Foundation - Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels)

With this Dear Colleague Letter (DCL), the sponsor highlights the interest of existing programs in the Directorate for Biological Sciences (BIO) and the Directorate for Engineering (ENG) in interdisciplinary research for the development of novel biological platforms that are capable of sensing and responding to emerging infectious agents. The mechanism of sensing should be adaptable and or evolvable such that the sentinel cells, or other appropriate biotechnology solutions, are robust to a range of emergent threats, and/or can easily be reprogrammed and deployed once a new threat is identified. The platform’s response should be one or more of the following: alert the user, destroy the threat, protect the host, initiate an immune response or other strategies that would ensure mitigation of the threat. Sentinel cells and organisms that detect and respond to infectious agents with expanding footprints in a host population or expanding host ranges are of particular interest, as the early detection of these infectious agents might have value in preventing future pandemics. In addition, fundamental science and technology that would lead to the development of the envisioned sentinel cells and organisms are also of interest. Investigators are encouraged not to be limited in their approach, but to think broadly about innovations leveraging biology and engineering to advance adaptable detection of emerging biological threats.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Novartis Foundation - COVID-19 Community Response Fund

In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Mercatus Center - COVID-19 Response: A Call for Ideas

The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Mozilla Open Source Support (MOSS) Awards Program - COVID-19 Solutions Fund

Mozilla will provide awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Open Road Alliance - Response to COVID-19

Open Road is offering charitable grants and loans to nonprofits and social enterprises impacted by COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Open Call for Innovation Focus Area: COVID-19: Rapid Sanitising Technology

In addition to its regular Open Call, DASA publishes Open Call innovation focus areas to increase awareness of some of the enduring challenges faced by defence and security stakeholders, and to stimulate the submission of relevant innovative proposals.

For the current focus area: COVID-19: Rapid Sanitising Technology, DASA is looking to identify, develop and demonstrate rapid sanitising technologies for ambulances that have transported a patient with suspected COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Paung Sie Facility - COVID-19 Prepare and Prevent Grants

These quick impact grants are designed to assist current or former partners to prepare for and conduct activities to build community capacity to prevent and prepare for COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Pollination Project - COVID-19 Rapid Response Grants

As of March of 2020, The Pollination Project has redirected all of our focus, support, and seed funding to uplifting the selfless actions of frontline grassroots volunteers working in response to COVID-19 (aka coronavirus) in their communities. Now until it is no longer needed, The Pollination Project will accept applications for volunteer community projects that address: direct needs around water, sanitation, and hygiene; community & emotional resilience; and virtualization of existing grassroots projects.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Pioneering Ideas: Exploring the Future to Build a Culture of Health

The Robert Wood Johnson Foundation (RWJF) has issued a call for proposals, “Pioneering Ideas: Exploring the Future to Build a Culture of Health”, seeking proposals that are primed to influence health equity in the future. They are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, they welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Priority Access Call for Work on Combating COVID-19

The Paul Scherrer Institute (PSI) has opened a “PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the COVID-19 virus and/or to improve the clinical or public health response and patient care.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Rapid Access Call for Proposals: SARS-CoV-2

Diamond Light Source are offering priority rapid access for groups who require instrument time for projects directly related to SARS-CoV-2 viral proteins.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Rapid Response Funding for Covid-19

Omidyar Network India has announced a call for proposals for rapid response funding to tackle the challenges posed by the Covid-19 situation and the consequent socio-economic impact. Proposals that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19 are welcomed. They are committing Rs. 7.5 crore (US $1 million) to this initiative.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)

01-May-2020, 01-Jun-2020, 01-Jul-2020, 03-Aug-2020, 01-Sep-2020, 01-Oct-2020, 02-Nov-2020, 01-Dec-2020, 04-Jan-2021, 01-Feb-2021, 01-Mar-2021, 01-Apr-2021, 03-May-2021, 01-Jun-2021, 01-Jul-2021, 02-Aug-2021, 01-Sep-2021, 01-Oct-2021, 01-Nov-2021, 01-Dec-2021, 03-Jan-2022, 01-Feb-2022, 01-Mar-2022, 01-Apr-2022, 02-May-2022, 01-Jun-2022, 01-Jul-2022, 01-Aug-2022, 01-Sep-2022, 03-Oct-2022
This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

SARS-COV-2 Diagnostics: Performance Data

FIND is conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays. To complement these evaluations, and in partnership with WHO in line with the sponsor’s official Collaborating Centre remit, the sponsor is endeavouring to centralize the collection of SARS-CoV-2 diagnostic performance data as a global public good. FIND is working closely with partners including the World Health Organization (WHO) in support of the global effort to combat the COVID-19 pandemic. In this respect, FIND is curating the overall diagnostic pipeline and tracking reported global diagnostic use, as well as conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Social Science Research Council - Just Tech Covid-19 Rapid-Response Grants

The Social Science Research Council (SSRC), as part of its Just Tech program, seeks proposals from across the social sciences and related fields that address the risks, opportunities, and challenges posed by public health surveillance stemming from the Covid-19 pandemic. The sponsor specifically encourages proposals that interrogate the role the public and private sectors may play in mitigating or exacerbating the health crisis, the effects of which are already unevenly distributed.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Staunton Farm Foundation - Emergency Fund for the COVID19 Pandemic

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

TechWatch Meeting Request

The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Turkish Philanthropy Funds - TPF COVID-19 Community Relief Fund

The sponsor has created the COVID-19 Community Relief Fund to support containment, response and recovery activities for those affected and for the responders.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Wellcome Trust - Epidemic Preparedness: COVID-19 Funding Call

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

West Coast Consortium for Technology & Innovation in Pediatrics - 2020 COVID-19 FlexGrants

The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic. Companies will be awarded grants up to $15,000 to support activities that apply or adapt their existing medical device to help manage the health impacts of the crisis on children. Medical devices with adult indications that are expanding or wish to expand their clinical indication to pediatrics are welcome to apply.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

September 2020 Application Deadlines

09/18/2020 - NIH/DHHS - RFA-OD-20-017 -- Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19. These devices are expected to actively detect VOCs from skin and oral cavities of COVID-19 patients, without being invasive, or affecting the integrity of the skin and oral cavity. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology or Gas Chromatography (GC). Therefore, this program is called SCENT, which stands for Screening for COVID-19 by Electronic-Nose Technology. This FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings. This FOA requires multidisciplinary collaborations to ensure project success. Disciplines may include: biomedical engineers, material scientists, biosensing experts, software engineers, chemists, dentists, clinicians, virologists, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

LOI (optional): August 18, 2020

Application Deadline: September 18, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/18/2020 - NIH/DHHS - RFA-OD-20-018 -- Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

LOI (optional): August 18, 2020

Application Deadline: September 18, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/18/2020 - NIH/DHHS - RFA-OD-20-020 -- Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit Direct to Phase II SBIR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

LOI (optional): August 18, 2020

Application Deadline: September 18, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/18/2020 - NIH/DHHS - RFA-OD-20-021 -- Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit Fast-Track STTR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

LOI (optional): August 18, 2020

Application Deadline: September 18, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

9/21/2020 - Pfizer Pharmaceuticals - Competitive Grant Program: Implementation of Telemedicine in Inflammatory Conditions: A Quality Improvement RFP

Pfizer Global Medical Grants (GMG) is issuing a Request for Proposals intending to support quality improvement for Healthcare Practitioners (HCPs) that treat RA, AD, and UC. Programs to help HCPs meet the ever-changing needs of patients during this challenging time will be supported. Individual projects requesting up to $250,000 will be considered.

More Information

Application Deadline: September 21, 2020

9/21/2020 - Medical Reserve Corps Small Grant Program

Funding Opportunity Number: EP-HIT-20-001

The Medical Reserve Corps (MRC) is a national network of 175,000 volunteers organized into approximately 850 local community-based groups which are committed to improving local emergency response capabilities, reducing vulnerabilities, and building community preparedness and resilience. MRC units organize and utilize local volunteers who want to donate their time and expertise to prepare for and respond to emergencies and to support steady-state preparedness initiatives. MRC volunteers include medical and public health professionals as well as other community members without healthcare backgrounds. MRC units bolster their community’s preparedness and emergency response infrastructures by providing supplemental personnel when needed, thus making those local communities less likely to be reliant on state and national resources. The majority of MRC units are sponsored by local health departments; other types of sponsoring organizations include emergency management agencies, local non-profits, and universities.

More Information

Application Deadline: September 21, 2020 11:59 PM (GMT – 05:00) Eastern Time (US & Canada)

 

 

9/21/2020 - Foundation for Women's Cancer - Diversity and Inclusion Health Equity Research Grant

Research among diverse populations has demonstrated disparities in treatment outcomes, access to care, genetic testing rates, and disease survival across many diseases. This new Diversity and Health Equity Research Grant is a one-year project where the funding is available for two $75,000 Research grants.

More Information

Letter of Intent Deadline: 21-Sep-2020

Application Deadline: 21-Dec-2020

09/24/2020 - Oak Ridge Institute for Science and Education - FDA Postgraduate COVID-19 Analysis Fellowship

A research opportunity is currently available with the Division of Plasma Protein Therapeutics (DPPT), in the Office of Tissues and Advanced Therapies (OTAT), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) located in Silver Spring, Maryland.

Application Deadline: September 24, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - Department of State - COVID-19 Small Grants Program

The Public Affairs Sections of the U.S. Mission to India, comprising the U.S. Embassy in New Delhi and the Consulates General in Hyderabad, Mumbai, Chennai, Kolkata, and North India, seeks to support effective coalitions that will bolster and leverage U.S.-India collaboration across a range of fields to fight COVID-19, in India and globally. The maximum award amount is $100,000.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - EPSRC UK-Robotics and Autonomous Systems (UK-RAS) Network - Medical Robotics for Contagious Diseases Challenge

30-Sep-2020 [LOI/Pre-App], 28-Oct-2020, 06-Nov-2020
The UK-RAS Network has announced a new Medical Robotics Challenge for Contagious Diseases.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - FDA-CBER-2020-0051 - FDA Influenza Immunity and Vaccination Postdoctoral Fellowship

A research opportunity is currently available in the Office of Vaccine Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - FDA-CBER-2020-0052 - FDA COVID-19 Diagnostic Test Fellowship

A research opportunity is currently available in the laboratory of Dr. Paul Carlson in the Office of Vaccine Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - NIH/DHHS - RFA-OD-20-019 -- Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)

NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

LOI (optional): August 31, 2020

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - NIH/DHHS - RFA-OD-20-023 -- Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

LOI (optional): August 31, 2020

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - Office of the Director, National Institutes of Health/NIH/DHHS - RFA-RM-20-020 -- NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional)

This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013. The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. The NIH Director’s Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Transformative Research Awards (through this FOA) or Early Independence Awards (through RFA-RM-20-021) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - Tasmanian Community Fund - COVID 19 Response Fund - Support, Connect and Rebuild - Medium Grants Program

The Tasmanian Community Fund is committed to making grants to community organizations that make a difference by improving the social, environmental, and economic wellbeing of the Tasmanian community.  The Tasmanian Community Fund is calling for medium applications that support Tasmanians and Tasmanian organizations to recover and rebuild from Covid19.  The TCF is seeking applications across three streams:

  • Support – supporting and meeting the needs of vulnerable people to ensure they are not left behind as a result of Covid19;
  • Connect – creating spaces and programs/processes to enable individuals and communities to reconnect and rebuild the social fabric of communities;
  • Rebuild – providing individual and organizational capacity building including options for realigning work and directions for the “new normal” and beyond.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

October 2020 Application Deadlines

10/01/2020 - Cystic Fibrosis Foundation - SARS-CoV-2 and Cystic Fibrosis Research Award

17-Jul-2020 [LOI/Pre-App], 01-Oct-2020
The Cystic Fibrosis Foundation is requesting Letters of Intent (LOIs) for basic science research projects that aim to improve our understanding of SARS-CoV-2 pathogenesis in cystic fibrosis. As the COVID-19 pandemic evolves, additional data will become available to shed light on populations that may have an increased susceptibility for contracting the disease as well as those who may experience a range in illness severity associated with this virus.

Letter of Intent Deadline: July 17, 2020

Application Deadline: October 1, 2020

More Information

10/01/2020 - Federation of State Medical Boards Foundation - FSMB Foundation COVID-19 State Response Grants

FSMB Foundation COVID-19 Grants are designed to offer state medical and osteopathic boards and other health care organizations funding support for the study of state responses to the COVID-19 pandemic. The long-term goal of the program is to support the development and implementation of sustainable models and policies that can guide state preparedness and responses to similar emergencies in the future, as well as their capacity for recovery planning

Letter of Intent Deadline: October 1, 2020

Application Deadline: December 15, 2020

More Information

10/01/2020 - International AIDS Society - Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme

The CIPHER Grant Programme directly supports the development of early-stage investigators, awarding up to US$150,000 for up to two years to address research gaps in paediatric and adolescent HIV in resource-limited settings. The purpose of the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme is to fund research projects with the potential to address critical research questions that remain unanswered in the global response in order to inform policy change and ensure better outcomes in infants, children and adolescents living with and affected by HIV in resource-limited settings. Designed for early-stage investigators, a key aim of the programme is to build research capacity within resource-limited settings by fostering the next generation of investigators in paediatric and adolescent HIV. It is intended to attract young investigators from inside and outside the field of HIV. This will help encourage innovative ideas and lead to the design of evidence-based approaches and interventions to overcome major obstacles in the field.

Application Deadline: October 1, 2020

More Information

10/05/2020 to 01/07/2021 - Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)

05-Oct-2020, 07-Jan-2021

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation. This FOA will use the NIH Research Project (R01) award mechanism.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

10/05/2020 -NOT-MD-20-025- Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities

National Institutes of Health/DHHS
Notice Number: NOT-MD-20-025

The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.

Application Deadline: October 5, 2020

More Information

10/05/2020 to 06/05/2022 - Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)

05-Oct-2020, 05-Feb-2021, 05-Jun-2021, 05-Oct-2021, 05-Feb-2022, 05-Jun-2022

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.

A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed.

This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

10/05/2020 - Genentech - Health Equity Innovations Fund

This call for grant proposals will support action-oriented research, demonstration projects, and programs to build the evidence base needed to promote health equity and reduce disparities in healthcare access, quality, and outcomes amongst populations facing the greatest needs – particularly communities of color. Funded proposals will develop, test, and/or scale strategies and interventions that reduce disparities and promote health equity. Successful proposals will also support health systems and hospitals, practitioners, advocates, community leaders, patients and caregivers, and decision-makers in setting priorities and allocating resources towards solutions that improve the health and wellbeing of historically underserved patients within Genentech’s disease areas of focus. Research projects must be U.S. based.

Letter of Intent Deadline: August 10, 2020

Application Deadline: October 5, 2020

More Information

10/05/2020 to 01/07/2024 - NIH/DHHS - RFA-OD-20-016 -- Emergency Awards: RADx-RAD Multimodal COVID-19 Surveillance Methods for High Risk Clustered Populations (R01 Clinical Trial Optional)

05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024
NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. The funding for this initiative is provided form the Paycheck Protection Program and Health Care Enhancement Act, 2020.   ?

More Information

10/06/2020 to 10/08/2021 - National Institute on Drug Abuse/NIH/DHHS - Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 7 priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service;6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies (e.g., the opioid crisis); 7) research collecting and examining data on the risks and outcomes associated with substance use and COVID-19 infection in the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).

Application Deadline: 06-Oct-2020 , 08-Feb-2021 , 08-Jun-2021 , 08-Oct-2021

More Information

10/09/2020 - Association for Frontotemporal Degeneration - Pilot Grant for Basic Science Research

AFTD Pilot Grants provide seed funding for innovative research with the potential to improve the understanding and treatment of frontotemporal degeneration (FTD) across the full spectrum of FTD disorders: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS. Pilot Grant-funded projects are intended to generate data that will support follow-on funding applications to the National Institutes of Health or other public or private agencies.

Application Deadline: October 9, 2020

More Information

10/13/2020 - RFA-HG-20-039 -- Laboratory, Data Analysis, and Coordinating Center (LDACC) for the Developmental Genotype-Tissue Expression Project (U24 Clinical Trial Not Allowed)

Funding Opportunity Announcement Number: RFA-HG-20-039

The National Human Genome Research Institute (NHGRI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development are coordinating efforts for establishing a Developmental Genotype-Tissue Expression (dGTEx) Project, to catalog and analyze transcriptional profiles from a wide variety of tissues obtained from neonates, children, and adolescents in a post-mortem setting. The purpose of this FOA is to solicit applications to develop and implement a Laboratory, Data Analysis, and Coordinating Center (LDACC) for the Developmental Genotype-Tissue Expression (dGTEx) Project. The LDACC will perform 2 major functions: a molecular laboratory, and a data analysis and coordinating center. As a molecular laboratory, the LDACC will work with the Biospecimen Procurement Center (BPC) funded by NICHD to process tissue samples for sequencing and biobanking. Responsibilities as a data analysis and coordinating center include ensuring close coordination with the BPC, monitoring study progress and laboratory performance, performing basic analysis of data for gene expression analyses, and harmonizing and submitting datasets to be deposited in repositories such as the AnVIL (Analysis, Visualization, and Informatics Lab-space).

Letter of Intent Deadline: October 13, 2020

Application Deadline: November 12, 2020

More Information

10/30/2020 - Fundación MAPFRE - Ignacio H. de Larramendi Research Grants

In the 2020 call, the sponsor is awarding Research Grants totaling 240,000 Euros to provide financial support for undertaking research projects in areas of Health Promotion.

Application Deadline: October 30, 2020

More Information

10/31/2020 - Ferring COVID-19 Investigational Grants

Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects on SARS-CoV-2 on reproduction, pregnancy, and foetal/neonatal health. The programme will provide a limited number of research grants up to €25,000 for each application

Application Deadline: October 31, 2020

More Information

10/31/2020 - Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

The latest BARDA BAA is amendment 12 posted on February 10, 2020 which incorporates changes to AOI 7-Diagnostics. BARDA is now accepting submissions to AOI 7.7 for development of assays for coronaviruses. Due to an overwhelming response to Area of Interest 7, BARDA is temporarily closing AOI’s; Innovations (7.1), biothreats (7.2), antibiotic resistance (7.3) and influenza (7.6). AOI’s radiation exposure/biodosimetry (7.4), and chemical threat exposure (7.5) remain closed.

The final whte paper submission deadline is October 31, 2020.

The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

More Information

10/31/2020 - Department of the Army - Domestic Manufacturing Capacity Expansion

Department of the Army
Funding Opportunity Number: W911QY-20-S-0018

The recipient shall expand existing domestic Continental US (CONUS) based manufacturing capacity for COVID-19 vaccine consumables products. The recipient shall identify, develop and qualify new US-based manufacturing capacity for utilization with USG (BARDA and affiliate partners) COVID-19 vaccines. Expansion of existing domestic capacity shall be through expansion of manufacturing capabilities in existing and new recipient facilities.

Application Deadline: October 31, 2020

More Information

10/31/2020 - WorkSafeBC - 2020 Specific Priorities - Impacts of COVID-19 - Request for Proposals

The impacts of COVID-19 to BC workers, employers and the workers’ compensation system are broad and diverse. COVID-19 has changed the way work is done. Including where and how workers are expected to perform their job and how they interact with the workplace. New ways of working present new risks and challenges, while also providing new opportunities. Safe and durable return to work and recovery of injured workers requires new supports and changes to care delivery and return to work planning, while prevention approaches must adapt to new guidelines, workplaces and technologies. WorkSafeBC is interested in research projects to address both direct and indirect impacts arising from the COVID-19 pandemic unique to occupational health and safety, injured or ill worker recovery, and safe and sustainable return to work or stay-at-work.

Application Deadline: October 31, 2020

More Information

10/31/2020 - WorkSafeBC - Specific Priorities Research Grants

WorkSafeBC’s Research Services funds are designed to address operational need and help answer key questions in occupational health and safety and workers’ compensation. These grants support short-term, primary and secondary research of immediate relevance. This research gives us the strongest scientific evidence to use when developing policy and practice.

Application Deadline: October 31, 2020

More Information

November 2020 Application Deadlines

11/04/2020 - RFA-DK-20-011 - Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)

Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death.

There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death.

The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC) will develop and test interventions that aim to reduce morbidity compared with usual care in Stage 2 and 3 AKI survivors. This FOA pertains to the CCs.

Application Deadline: November 4, 2020

More Information

11/04/2020 - RFA-DK-20-012 - Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)

Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death.

There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death.

The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium, composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC), will develop and test interventions that aim to reduce morbidity compared with usual care in Stage 2 and 3 AKI survivors. This FOA pertains to the SDRC.

Application Deadline: November 4, 2020

More Information

11/10/2020 - RFA-DE-21-001 - Characterizing causal mechanisms to prevent dental fear and anxiety (R01 Basic Experimental Studies with Humans Required)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to test causal mechanisms underlying the etiology or prevention of dental fear, anxiety, or phobia. Novel insights about the causal forces that initiate, shape, or impede the development of dental fear will be essential for informing evidence-based interventions to prevent dental fear.

Application Deadline: November 10, 2020

More Information

11/18/2020 - Ecology and Evolution of Infectious Diseases (EEID)

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.

Application Deadline: November 18, 2020

More Information

11/17/2020 - RFA-AA-20-009 - Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV in patients with alcohol use disorders.

Application Deadline: November 17, 2020

More Information

December 2020 Application Deadlines

12/02/2020, 03/02/2021 - PAR-20-243 - Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.

Application Deadline: 12/02/2020, 03/02/2021

More Information

12/16/2020 - RFA-DK-20-021 - Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.

Application Deadline: December 16, 2020

More Information

12/31/2020 - Travel and subsistence funding to support LMIC engagement during the COVID-19 outbreak

The awards will provide travel and subsistence funding to appropriately qualified public health professionals, clinicians and academics who wish to offer science and technical advice to support the immediate response to COVID-19 in low and middle-income countries. The awards are open to applicants who have a substantive position at a UK higher education institution or research organisation.

Application Deadline: December 31, 2020

More Information

12/31/2020 - IBSA Foundation for Scientific Research - Fellowship Program

The IBSA Foundation provides fellowships to young researchers under the age of 40, from Universities and Institutes around the world, who have distinguished themselves for their skills and have ongoing projects of particular relevance in four specific fields of medical discipline – Dermatology, Endocrinology, Fertility, Orthopaedics-Rheumatology and Pain Medicine – to which is added the Special Edition which changes every year.

Application Deadline: December 31, 2020

More Information

February 2021 Application Deadlines

02/03/2021 to 10/30/2023 - National Institute for Occupational Safety & Health/CDC/DHHS - NIOSH Centers of Excellence for Total Worker Health® (U19)

NIOSH/CDC invites applications for the NIOSH Centers of Excellence for Total Worker Health (TWH). The purpose of this FOA is to solicit meritorious applications for Centers of Excellence for TWH to develop and conduct a broad range of multidisciplinary research, intervention, outreach and education, and evaluation activities that advance the overall safety, health, and well-being of the diverse population of workers in our nation. Center structure should take advantage of diverse scientific resources and focus on local, regional, or national worker safety and health issues. Centers should emphasize creating and implementing evidence-based solutions to address evolving challenges and opportunities related to worker safety, mental and physical health, and well-being. Collaborations in partnership with academic institutions, nonprofit organizations, and other groups focused on occupational safety and health are expected. Applicants must concisely describe the occupational health burden within their service area and directly link research and outreach activities to help alleviate the burden. Applicants should also clearly articulate the anticipated impacts of the proposed work, both during the project period and beyond.

Application Deadline: 03-Feb-2021 , 29-Oct-2021 , 28-Oct-2022 , 30-Oct-2023

More Information

02/28/2021 - Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing

Department of the Army
Funding Opportunity Number: W911QY-20-S-0019

Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing. This Prototype project is a combination of an agile development activity, design, and demonstration of the technical and operational utility of a product to move forward to FDA licensure/approval.

Application Deadline: February 28, 2021

More Information

April 2021 Application Deadlines

04/17/2021 - Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)

Open Date (Earliest Submission Date): April 17, 2021

Letter of Intent Due Date(s): 30 days prior to the application due date


Application Deadlines: May 17, 2021, May 17, 2022, May 17, 2023

More Information

04/29/2021 - National Institute of Allergy and Infectious Diseases/NIH/DHHS - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

Application Deadline: April 29, 2021

More Information

04/29/2021 - National Institute of Allergy and Infectious Diseases/NIH/DHHS - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

Application Deadline: April 29, 2021

More Information

May 2021 Application Deadlines

05/28/2021 - Department of State - COVID-19 Private Sector Engagement & Partnership Fund

The U.S. Department of State, Office of Global Partnerships (E/GP) is pleased to announce the COVID-19 Private Sector Engagement & Partnership Fund (Fund) Annual Program Statement (APS) that will be used make assistance awards. Through this APS, the Department of State (DOS) announces its desire to engage private sector partners to expand and amplify the Department’s COVID-19 response. The Fund seeks to support private sector interventions and build upon private sector investments in response to the virus.

Application Deadline: May 28, 2021

More Information

February 2023 Application Deadlines

02/03/2023 - BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement

Please see Special Instructions 001 Issuance for Easy Broad AgencyAnnouncement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of itsEZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV. See attachment(s).This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest(AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) inthe Office of Biomedical Advanced Research and Development Authority(BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal AcquisitionRegulation (FAR). Abstract submissions selected for award are consideredto be the result of full and open competition and in full compliance with41 U.S.C.

Application Deadline February 3, 2023

More Information

GCO Funding Opportunities

Monthly and continuous submission funding opportunity packets are available on the GCO Funding Opportunities web page.

STAY CONNECTED

Sign up for the Research Listserv to stay up to date with the latest news and events.